Table 1. Characteristic of 81 included guidelines.
| Categories | SARS-CoV (n=21) | EBOV (n=11) | MERS-CoV (n=9) | ZIKV (n=10) | SARS-CoV-2 (n=30) |
|---|---|---|---|---|---|
| Publication year since outbreak† | |||||
| ≤1 year | 13 (61.9%) | 5 (45.5%) | 5 (55.6%) | 10 (100.0%) | 30 (100.0%) |
| >1 year | 8 (38.1%) | 6 (54.5%) | 4 (44.4%) | 0 (0.0%) | – |
| Publication country/region | |||||
| International | 1 (4.8%) | 6 (54.5%) | 5 (55.6%) | 6 (60.0%) | 7 (23.3%) |
| China | 15 (71.4%) | 2 (18.2%) | 1 (11.1%) | 0 (0.0%) | 13 (43.3%) |
| America | 3 (14.3%) | 1 (9.1%) | 0 (0.0%) | 4 (40.0%) | 9 (30.3%) |
| Others | 2 (9.5%) | 2 (18.2%) | 3 (33.3%) | 0 (0.0%) | 1 (3.3%%) |
| Organization | |||||
| WHO | 1 (4.8%) | 5 (45.4%) | 5 (55.5%) | 5 (50.0%) | 7 (23.3%) |
| CDC | 2 (9.5%) | 2 (18.1%) | 0 (0.0%) | 4 (40.0%) | 10 (33.3%) |
| Government | 2 (9.5%) | 1 (9.0%) | 2 (22.2%) | 0 (0.0%) | 8 (26.6%) |
| Society/association | 7 (33.3%) | 1 (9.0%) | 2 (22.2%) | 1 (10.0%) | 1 (3.3%) |
| Hospital | 3 (14.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (13.3%) |
| University | 0 (0.0%) | 1 (9.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Not reported | 6 (28.6%) | 1 (9.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Scope & purpose | |||||
| Overall management | 5 (23.8%) | 1 (9.0%) | 3 (33.3%) | 2 (20.0%) | 7 (23.3%) |
| Prevention | 2 (9.5%) | 3 (27.2%) | 2 (22.2%) | 2 (20.0%) | 7 (23.3%) |
| Diagnosis | 0 (0.0%) | 0 (0.0%) | 1 (11.1%) | 1 (10.0%) | 1 (3.3%) |
| Prevention and treatment | 1 (4.8%) | 0 (0.0%) | 1 (11.1%) | 0 (0.0%) | 3 (10.0%) |
| Screening | 0 (0.0%) | 0 (0.0%) | 1 (11.1%) | 0 (0.0%) | 0 (0.0%) |
| Diagnosis and treatment | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (10.0%) |
| Nursing | 0 (0.0%) | 2 (18.1%) | 0 (0.0%) | 0 (0.0%) | 1 (3.3%) |
| Others | 11 (52.3%) | 5 (45.4%) | 1 (11.1%) | 5 (50.0%) | 8 (26.6%) |
| Publication format | |||||
| Journal | 17 (81.0%) | 4 (36.3%) | 3 (33.3%) | 3 (30.0%) | 1 (3.3%) |
| Website | 4 (19.0%) | 7 (63.6%) | 6 (66.6%) | 7 (70.0%) | 29 (96.7%) |
| Development method | |||||
| Evidence-based | 1 (4.8%) | 4 (36.3%) | 4 (44.4%) | 3 (30.0%) | 3 (10.0%) |
| Non-evidence-based | 20 (95.2%) | 7 (63.6%) | 5 (55.5%) | 7 (70.0%) | 27 (90.0%) |
| Funding | |||||
| Reported | 0 (0.0%) | 2 (18.1%) | 1 (11.1%) | 0 (0.0%) | 1 (3.3%) |
| Not reported | 21 (100.0%) | 9 (81.8%) | 8 (88.8%) | 10 (100%) | 29 (96.6%) |
Publication year within an outbreak: 2003 (SARS-CoV), 2014 (Ebola virus), 2015 (MERS-CoV), 2016 (Zika virus), 2020 (SARS-CoV-2). CDC, Centers for Disease Control and Prevention of the United States; Chinese Center for Disease Control and Prevention; SARS-CoV, Severe Acute Respiratory Syndrome coronavirus; EBOV, Ebola virus; MERS-CoV, Middle East Respiratory Syndrome coronavirus; ZIKV, Zika virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.